Novartis
EC approves Novartis’s Kesimpta for relapsing multiple sclerosis
The European Commission has approved Novartis’s Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults…
Novartis to divest select Sandoz US portfolio to Aurobindo for $900m
Novartis has signed an agreement to sell parts of its Sandoz US business to Aurobindo Pharma USA for a cash…
Novartis receives EC approval for Kymriah to treat two cancers
The European Commission (EC) has granted approval for Novartis' Kymriah to treat patients with B-cell acute lymphoblastic leukaemia (ALL) and…
Novartis’ migraine drug Aimovig gets EC approval
Novartis has obtained approval from the European Commission (EC) for the use of Aimovig (erenumab) to prevent migraine in adults…
Novartis signs $1bn licensing deal with MorphoSys and Galapagos
Novartis Pharma has signed a worldwide, exclusive agreement to licence atopic dermatitis drug candidate MOR106, which is being jointly development…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
FDA approves expanded indication for Novartis drug Kisqali
Novartis has obtained approval from the US Food and Drug Administration (FDA) for its Kisqali (ribociclib) to treat hormone-receptor positive,…
Novartis and Sandoz withdraw medicines from US over packaging concerns
Novartis and its affiliated Sandoz division have voluntarily recalled certain lots of 12 blister packs of medicines from the US…